Search - Université de Rennes Access content directly

Filter your results

9 Results
authFullName_s : Anne Banos

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial

Anne Bouvier , Jean-Francois Hamel , Jacques Delaunay , Eric Delabesse , Pierre-Yves Dumas et al.
European Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles hal-03604930v1

Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study

Marie Péan de Ponfilly-Sotier , Vincent Jachiet , Ygal Benhamou , Constance Lahuna , Benoit de Renzis et al.
Clinical and experimental rheumatology, 2022, 40 (7), pp.1336-1342. ⟨10.55563/clinexprheumatol/nbn38d⟩
Journal articles hal-03968172v1
Image document

Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Gaëlle Laboure , Marie-Cecile Parrens , Anjarasoa Tsaranazy , Magali Bordier , Steven Le Gouill et al.
55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015
Conference poster hal-01290432v1

Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma

Guillemette Fouquet , Lionel Karlin , Margaret Macro , Denis Caillot , Murielle Roussel et al.
Blood, 2015, 126 (23), pp.1831
Journal articles hal-01300804v1

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Xavier Leleu , Lionel Karlin , Margaret Macro , Cyrille Hulin , Laurent Garderet et al.
Blood, 2015, 125 (9), pp.1411-7. ⟨10.1182/blood-2014-11-612069⟩
Journal articles hal-01141134v1
Image document

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Norbert Schmitz , Lorenz Truemper , Krimo Bouabdallah , Marita Ziepert , Mathieu Leclerc et al.
Blood, 2021, 2020008825, ⟨10.1182/blood.2020008825⟩
Journal articles hal-03163608v1
Image document

R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)

Thierry Lamy , Gandhi Damaj , Pierre Soubeyran , Emmanuel Gyan , Guillaume Cartron et al.
Blood, 2018, 131 (2), pp.174-181. ⟨10.1182/blood-2017-07-793984⟩
Journal articles hal-01635792v1

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Arnaud Pigneux , Christian Récher , Marie C. Bene , Julien Asselineau , Ariane C. Mineur et al.
Blood, 2015, 126 (23)
Journal articles hal-01295674v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1